Kordata Dynamics Emerges From Stealth With Launch of AI Platform for Next-Generation Precision Clinical Trials and Backing From BIOS Health Investors

• Kordata Dynamics has launched a new model of precision clinical trials, with an AI platform powered by BIOS Health, designed to improve quality, speed, and accessibility throughout the healthcare systems.
• The announcement came in the same week the FDA introduced a pilot program for real-time clinical trials, responding to an inflection point in US appetite for advancements in this industry.
• Kordata has chosen to position its first site in Bakersfield, CA, a key strategic foundation for growth into hospitals and clinical centers across the country

BAKERSFIELD, Calif.--(BUSINESS WIRE)--Kordata Dynamics exits stealth with a pre-seed funding round from MAVRK Celestia Fund, Kern Venture Group and Digital Neural Infrastructure Holdings (DNIH). A spin-out from BIOS Health, Kordata is redefining clinical trial execution, introducing a new model for AI-powered precision clinical trials at scale.

Kordata’s platform will enable fast, high-quality results, even in complex therapy areas. Its unique clinical trials model also incorporates BIOS’ proprietary AI precision dosing technology NeuroTune, which can give real-time insights into patient responses to drugs and interventions by processing neural data, collected from multiple invasive or non-invasive data sources, to characterise the body’s own reactions to medicines.

With an initial focus on precision neuromodulation and precision neural therapies, Kordata is targeting a space that has a $26 billion backlog in clinical trials. These are relevant to a wide range of conditions; including major brain disorders such as Alzheimer’s, Parkinson’s, Epilepsy; and the drug resistant forms of many chronic diseases such as Cardiovascular Disease, Autoimmune conditions and Autonomic Dysfunction.

Kordata Dynamics is built on the conviction that the future of clinical research doesn’t have to be slow, failure prone, or inaccessible. Last month the FDA also recognised this as a focus area for the industry, with its recent initiative for real-time monitoring of clinical trial data.

“That’s an exciting development for our field, and exactly what our model is designed for,” said Emil Hewage, CEO of BIOS Health and Kordata. “The vision is for high quality trials that recruit in 3-6 months rather than over many years, provide clear data, and enfranchise vastly more patients and clinicians in the advancement of medicine.”

High quality, fast, clinical trials are essential for trusted and affordable medicines. For the past 50 years, only 5% of US hospitals have supported clinical trials. After global efforts to speed up trials in the wake of the pandemic, countries like China can now run trials at national scale and are competing for most of the new breakthroughs in medicine.

Kordata’s real time, AI-based approach offers an opportunity for the US market to become more competitive. By increasing speed, improving precision and enabling the remaining 95% of US hospitals to run clinical trials.

“Powered by BIOS’ technology, we can simplify dosing for complex medicines. We have collaborated with KVG, DNIH and MAVRK to launch Kordata Dynamics to take this further. The combination should unlock the treatments which otherwise might not come to light,” said Hewage.

Strategic location

Bakersfield was selected as Kordata’s inaugural city for strategic reasons that reflect the company’s mission to make precision medicine more accessible. The central valley region is home to major industries driving 40% of the GDP of California alongside a data driven culture honed on the frontiers of aerospace, agriculture and energy, but this region also brings a large patient population with limited access to cutting-edge clinical research.

Key government, local relationships; an established network of physicians; partners; and hospitals provide the foundation for rapid development and deployment. Kordata Dynamics will also expand this local network, connecting clinicians in the US to experts and academics in scientific hubs around the world, enabling knowledge-sharing and faster innovation cycles.

Kordata Dynamics President, Dawn McCollough has a proven 30-year track record in clinical trials, with involvement in more than 15,000 trials and seeing 27 drugs to market. Also a former Executive at Biogen and Novartis, she said, “At Kordata, we enable sponsors, sites, researchers and clinicians to access the benefits of AI-powered precision medicine tools previously out of reach, helping unlock the kind of high-quality, precise data and efficiencies that drives breakthroughs.”

According to her, the company plans to connect these key ingredients to the larger clinical trial environment where access to funding, stifling of innovation and lengthy timelines are common stories. We honor the need for the best quality products and options for patients and along with that using technology and advancements that can extrapolate those possibilities. We're excited to get off the ground, starting in Bakersfield.”

About Kordata Dynamics

Kordata Dynamics is a US-based clinical trial innovation company leveraging Real time clinical trial execution technology and BIOS Health’s proprietary AI and neural biomarker technology to make precision medicine faster, smarter, and more accessible. Kordata provides a new model to simplify the capture, processing, and interpretation of large-scale precision health data across regional medical centers, transforming complex clinical trial processes into simple, repeatable and high quality work. Redefining how clinical trials are designed, run, and scaled. Backed by Kern Venture Group, MAVRK Celestia Fund, BIOS Health, and Digital Neural Infrastructure Holdings, Kordata Dynamics has been built in the heart of California and designed for global impact.

For more information, visit: kordatadynamics.com

About BIOS Health

BIOS is a pioneering neural interface company building the infrastructure on which future neural treatments will be discovered, developed, and delivered. BIOS has developed neural interfaces and AI that, for the first time, can read and write the body’s neural data, or ‘code’, to understand and correct those signals in real-time. BIOS envisions a new field of digital health treatments that use this new data-driven insight from the nervous system to create better, more targeted medicine. Neural digital therapies will use BIOS' software to understand the effects on the nerves, leading to more precise creation of pharmaceuticals and software-delivered treatments direct to the nervous system. BIOS’ proprietary AI precision dosing technology, NeuroTune, can give real-time insights into a patient’s responses to drugs and interventions by processing neural data, collected in real time from multiple invasive or non-invasive data sources. Neurotune is intended to help patients and their doctors interpret and optimise their body’s own reactions to medicines. Neurotune has been validated in a number of therapy areas and is now being made available for frontier clinical research via Kordata Dynamics.

For more information, visit: www.bios.health